|
AU2016231532A1
|
|
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
MX2019007950A
|
|
Tripeptide epoxy ketone protease inhibitors.
|
|
WO2015021376A1
|
|
Immunoglobulin expression levels as biomarker for proteasome inhibitor response
|
|
WO2015009888A2
|
|
Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
|
|
AU2014240122A1
|
|
Dipeptide and tripeptide epoxy ketone protease inhibitors
|
|
AR095426A1
|
|
TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
|
|
TW201422255A
|
|
Modified release formulations for oprozomib
|
|
AU2013292636A1
|
|
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
US2014105921A1
|
|
Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
|
|
KR20200130748A
|
|
Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
|
|
AU2013203857A1
|
|
Crystalline tripeptide epoxy ketone protease inhibitors
|
|
AU2013203525A1
|
|
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
AU2013203467A1
|
|
Compounds for immunoproteasome inhibition
|
|
AU2013203566A1
|
|
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
AU2012261655A1
|
|
Composition for proteasome inhibition
|
|
NZ602490A
|
|
Cylodextrin complexation methods for formulating peptide proteasome inhibitors
|
|
AU2013204448A1
|
|
Cylodextrin complexation methods for formulating peptide proteasome inhibitors
|
|
AU2012203602A1
|
|
Compounds for proteasome enzyme inhibition
|
|
AU2012202284A1
|
|
Novel substrate for Rpn11 enzymatic activity
|
|
AU2012200797A1
|
|
Peptide epoxyketones for proteasome inhibition
|
